Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone + follitropin alfa + lutropin alfa
- Development stage
- Unknown
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Transdermal, Subcutaneous
01
Overview
Testosterone + FSHr-LHr is an investigational combination drug regimen studied for the treatment of infertility in women classified as low responders undergoing in vitro fertilization (IVF). The protocol involves a pre-treatment phase with transdermal testosterone, which is intended to upregulate follicle-stimulating hormone (FSH) receptors in the ovaries, followed by controlled ovarian stimulation using a combination of recombinant follicle-stimulating hormone (follitropin alfa) and recombinant luteinizing hormone (lutropin alfa). This approach aims to enhance ovarian sensitivity to gonadotropins and improve the number of oocytes retrieved and clinical pregnancy rates in patients who have previously shown a poor response to standard stimulation protocols. The regimen was primarily evaluated in clinical trials sponsored by the Hospital Clinic of Barcelona.
- Other names
- testosterone + FSHr + LHrtestosterone + recombinant FSH + recombinant LHtestosterone + FSHr-LHr
02
Targets
AR (Adrenergic receptors)FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on testosterone + follitropin alfa + lutropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone + follitropin alfa + lutropin alfa.